Dr Reddy’s anti cholesterol drug’s second phase trial in May

Hyderabad | Updated on March 12, 2018 Published on February 22, 2011

A new anti cholesterol drug being developed by Dr Reddy’s Laboratories (DRL) is set to enter into second phase of trial in May, Chairman of the company, Mr Dr Anji Reddy, said here on Tuesday.

There are only two companies other than Dr Reddy’s developing a similar kind of drug, Roche and Merck and they have already entered into third phase of the drug trial.

The completion of Phase-I implies that the company has already found the drug to be safe though the efficacy and other issues will have to be tested in the subsequent phases.

“We are going to take our drug called DRF17822 into Phase-II in the month of May. We are going to start as the third company in the world. It is known as the CETP inhibitor which has the potential to increase your HDL by 110 per cent,” Mr Anji Reddy said in his speech during BioAsia-2011 - a three day event of global bio - business forum.

The drug is intended to reduce the risk of atherosclerosis (a cardiovascular disease) by improving blood lipid levels.

However, he said it would take some years to come out successfully from the Phase-II trials and enter into Phase—III.

Replying to queries on the market size, Reddy said it would be the first of its kind drug and market for the same is huge adding this drug discovery will change the image of Dr Reddy’s.

“This should change the way cardiovascular diseases are treated in future. And will prove that we are not copy cats and that we can also discover drugs,” he said.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 22, 2011
This article is closed for comments.
Please Email the Editor